نتائج البحث

PCNEO, a New Proficiency Testing Program for Flow Cytometric Analysis of Plasma Cell Neoplasms From the College of American Pathologists Diagnostic Immunology and Flow Cytometry Committee.

• Authors : Dorfman DM; From the Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Dorfman).; Devitt KA

Subjects: Flow Cytometry*/Flow Cytometry*/Flow Cytometry*/methods ; Flow Cytometry*/Flow Cytometry*/Flow Cytometry*/standards ; Laboratory Proficiency Testing*

• Source: Archives of pathology & laboratory medicine [Arch Pathol Lab Med] 2024 Jun 01; Vol. 148 (6), pp. 699-704.Publisher: College of American Pathologists Country of Publication: United States NLM ID: 7607091 Publication Model: Print Cited Medium: Internet

تفاصيل العنوان

Cytogenetic, Clinical, Hematologic, Demographic, Immunohistochemical, and Flow Cytometry Characteristics of Patients with Plasma Cell Neoplasm in Five Years: A First Report from Iran.

• Authors : Shokripour M; Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.; Hosseini SE

Subjects: Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/pathology ; Neoplasms, Plasma Cell*/Neoplasms, Plasma Cell*/Neoplasms, Plasma Cell*/diagnosis ; Neoplasms, Plasma Cell*/Neoplasms, Plasma Cell*/Neoplasms, Plasma Cell*/epidemiology

• Source: Iranian journal of medical sciences [Iran J Med Sci] 2024 Feb 01; Vol. 49 (2), pp. 77-87. Date of Electronic Publication: 2024 Feb 01 (Print Publication: 2024).Publisher: Shiraz University of Medical Sciences Country of Publication: Iran NLM ID: 8104374 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

The Involvement of LAG-3 positive Plasma Cells in the Development of Multiple Myeloma.

• Authors : Kreiniz N; The Division of Hematology, Bnai Zion Medical Center, Sderot Eliyahu Golomb 47, Haifa 3339419, Israel.; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Efron St 1, Haifa 3525433, Israel.

Subjects: Multiple Myeloma* ; Neoplasms, Plasma Cell* ; Paraproteinemias*

• Source: International journal of molecular sciences [Int J Mol Sci] 2023 Dec 31; Vol. 25 (1). Date of Electronic Publication: 2023 Dec 31.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

تفاصيل العنوان

The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review.

• Authors : Kleinstern G; School of Public Health, University of Haifa, Haifa, Israel.; Division of Computational Biology, Mayo Clinic, Rochester, MN, USA.

Subjects: Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/genetics ; Lymphocytosis*/Lymphocytosis*/Lymphocytosis*/genetics

• Source: Leukemia & lymphoma [Leuk Lymphoma] 2023 Apr; Vol. 64 (4), pp. 788-798. Date of Electronic Publication: 2022 Dec 28.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study.

• Authors : Nahi H; Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden.; Usmani SZ

Subjects: Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/drug therapy ; Neoplasms, Plasma Cell*; Humans

• Source: Leukemia & lymphoma [Leuk Lymphoma] 2023 Feb; Vol. 64 (2), pp. 468-472. Date of Electronic Publication: 2023 Jan 02.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Monoclonal B-cell Lymphocytosis - a review of diagnostic criteria, biology, natural history, and clinical management.

• Authors : Tang C; Department of Haematology and Flow Cytometry, Laverty Pathology, Sydney, Australia.; Department of Haematology, Gosford Hospital, Gosford, Australia.

Subjects: Lymphocytosis*/Lymphocytosis*/Lymphocytosis*/diagnosis ; Lymphocytosis*/Lymphocytosis*/Lymphocytosis*/etiology ; Lymphocytosis*/Lymphocytosis*/Lymphocytosis*/therapy

• Source: Leukemia & lymphoma [Leuk Lymphoma] 2022 Dec; Vol. 63 (12), pp. 2795-2806. Date of Electronic Publication: 2022 Jun 29.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Mature B, T and NK-cell, plasma cell and histiocytic/dendritic cell neoplasms: classification according to the World Health Organization and International Consensus Classification.

• Authors : Ferry JA; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA. .; Hill B

Subjects: World Health Organization* ; Consensus*; Humans

• Source: Journal of hematology & oncology [J Hematol Oncol] 2024 Jul 08; Vol. 17 (1), pp. 51. Date of Electronic Publication: 2024 Jul 08.Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722

تفاصيل العنوان

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

• Source: A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed

تفاصيل العنوان

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ALUMMINATE)

• Source: A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple

تفاصيل العنوان

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

• Source: A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN

تفاصيل العنوان